Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Enterprise Value: 2012-2025

Historic Enterprise Value for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to $3.2 billion.

  • Ptc Therapeutics' Enterprise Value rose 73.17% to $3.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 94.09%. This contributed to the annual value of $2.3 billion for FY2024, which is 94.65% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Enterprise Value of $3.2 billion as of Q3 2025, which was up 69.38% from $1.9 billion recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Enterprise Value registered a high of $3.3 billion during Q3 2022, and its lowest value of $1.2 billion during Q4 2023.
  • Over the past 3 years, Ptc Therapeutics' median Enterprise Value value was $1.9 billion (recorded in 2025), while the average stood at $2.0 billion.
  • Examining YoY changes over the last 5 years, Ptc Therapeutics' Enterprise Value showed a top increase of 94.65% in 2024 and a maximum decrease of 59.15% in 2024.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Enterprise Value stood at $2.0 billion in 2021, then grew by 14.22% to $2.3 billion in 2022, then crashed by 48.44% to $1.2 billion in 2023, then soared by 94.65% to $2.3 billion in 2024, then spiked by 73.17% to $3.2 billion in 2025.
  • Its last three reported values are $3.2 billion in Q3 2025, $1.9 billion for Q2 2025, and $2.0 billion during Q1 2025.